Parving, H.H.

patient treatment diabetes study igf-i type 2 diabetes renin aliskiren effect blood pressure baseline reduction placebo level change type 1 diabetes plasma spironolactone subject autoregulation period nephropathy albuminuria signi ficantly renin inhibition signi blood pressure irbesartan hypertension spironolactone treatment igf-i gene polymorphism variant type combination igf-i levels table raas blockade kidney autoregulate gfr plasma renin activity polymorphism growth washout combination treatment clonidine variant ficantly inhibition allele blockade ang i inhibitor value antihypertensive ang ii result activity prorenin serum insulin journal diastolic blood pressure factor trial difference igf-i gene sample treatment period increase measurement hypertensive concentration erasmus university rotterdam endocrinology 1.73 m 2 method ficant parving follow-up ability